医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsui Chemicals Launched New Lens Material “UV+420cutTM”

2014年10月27日 AM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsui Chemicals, Inc. (TOKYO:4183) (President & CEO: Tsutomu Tannowa) announced that it commenced sales of a new breakthrough ophthalmic lens material that helps protect eyes from not only ultraviolet (10-400nm) light rays but also 400nm-420nm wavelength light.

Our eyes are constantly damaged by sunlight exposure and therefore it is important to protect eyes from UV exposure. Recent studies have shown, however, that shorter wavelength light from 400nm-420nm also damages the retina, which is the most vulnerable tissue of the eye, and this can be one of the factors which accelerates the development of Age-related Macular Degeneration (AMD) and cataracts. Although many conventional sunglasses, in addition to protecting from UV rays, provide protection from shorter wavelength light, general vision correction lenses do not. Mitsui Chemicals’ newly debuted lens material, “UV+420cutTM“, helps protect eyes from damaging short wavelength light.

This technology is used in the new “LUTINA® lenses of Tokai Optical Co., Ltd.

Mitsui Chemicals provides performance-driven lens materials ranging from high to low refractive indices as well as optimum coating materials for lenses to meet diversifying global market needs. It will continue to develop groundbreaking, value-added vision care materials.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141026005007/en/

CONTACT

Mitsui Chemicals
Yoko Kobayashi, +81-3-6253-2100
Corporate
Communications Division
yoko.kobayashi@mitsui-chem.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™